FRET

The technology is an ultra-sensitive optical biosensor based on the FRET principle, designed for identifying the initial, pre-aggregated pathological form of the Tau protein (CST). The innovation lies in the ability to detect specific conformational changes (CST), providing a molecular advantage over concentration-only tests.

In vitro validation (TRL 3) has been successfully completed, demonstrating the sensor's effectiveness on: